Lundbeck focuses on central nervous system drugs, including antidepressants, antipsychotics, and antiepileptic products. While incremental innovations and label expansions have helped Lundbeck ...

Denmark’s Lundbeck is bringing a third potential drug for Parkinson’s disease to the clinic – a human antibody that the company hopes will tackle the underlying cause of the condition.

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), although the company says the ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...